Issue Date: July 20, 2015
Siegfried Transfers A Plant To Celgene
Swiss fine chemicals maker Siegfried has sold a production building at its facility in Zofingen, Switzerland, to the biotech firm Celgene. The agreement builds on a contract signed 10 years ago under which Celgene has exclusive rights to capacity in Zofingen for production of the active ingredient in its multiple myeloma drug Revlimid. Separately, German and French authorities have green-lighted Siegfried’s acquisition, announced earlier this year, of three European custom synthesis sites from BASF.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society